Bejder, J, Andersen, A. B., Buchardt, R, Larsson, T. H., Olsen, N. V. & Nordsborg, N. B. (2017). Endurance, aerobic high-intensity, and repeated sprint cycling performance is unaffected by normobaric "Live High-Train Low": A double-blind placebo-controlled cross-over study. European Journal of Applied Physiology, 117 (5), 979-988. Zugriff am 10.03.2021 unter https://doi.org/10.1007/s00421-017-3586-0
APA-Zitierstil (7. Ausg.)Bejder, J., Andersen, A. B., Buchardt, R., Larsson, T. H., Olsen, N. V., & Nordsborg, N. B. (2017). Endurance, aerobic high-intensity, and repeated sprint cycling performance is unaffected by normobaric "Live High-Train Low": A double-blind placebo-controlled cross-over study. European Journal of Applied Physiology, 117(5), 979-988.
Chicago-Zitierstil (17. Ausg.)Bejder, J., A. B. Andersen, R. Buchardt, T. H. Larsson, N. V. Olsen, und N. B. Nordsborg. "Endurance, Aerobic High-intensity, and Repeated Sprint Cycling Performance Is Unaffected by Normobaric "Live High-Train Low": A Double-blind Placebo-controlled Cross-over Study." European Journal of Applied Physiology 117, no. 5 (2017): 979-988.
MLA-Zitierstil (9. Ausg.)Bejder, J., et al. "Endurance, Aerobic High-intensity, and Repeated Sprint Cycling Performance Is Unaffected by Normobaric "Live High-Train Low": A Double-blind Placebo-controlled Cross-over Study." European Journal of Applied Physiology, vol. 117, no. 5, 2017, pp. 979-988.